Detailed Narrative
Strong Q4 FY26 Performance Driven by Diversified Growth
Mold-Tek Packaging reported a healthy 13.4% overall sales growth for FY26, with Q4 showing robust performance. Pharma packaging was a standout, growing over 200% for the full year to INR34.4 crores and 37% in Q4. The Paint segment also contributed significantly with 13.4% sales growth for the year, including a 17% Q4 growth from Asian Paints and 60% volume growth from ABG. Additionally, Food & FMCG and Qpacks segments grew by 15% and 25% respectively, underpinning the overall healthy growth.
Operational Efficiencies from Hyderabad Consolidation
The company successfully consolidated five units in Hyderabad into two (Unit 1 and 10), leading to improved overall performance and efficiencies. This strategic move resulted in better EBITDA margins, with EBITDA per kg increasing by 8.4% from INR37.6 in the previous year to INR40.7 in FY26. Management expects the full benefits of this consolidation to be reflected in FY27, targeting an EBITDA per kg of INR42.5-43.
Strategic Capacity Expansion and Modernization
Mold-Tek is actively expanding its capacity across key segments. Pharma capacity is targeted to increase from 1,500 tons to 2,500 tons in FY27 through new investments. The Panipat facility, particularly for thin wall production, currently operating at 20-25% utilization, will see a 100% capacity expansion with 4 new machines arriving in July, aiming for 40-50% utilization next year. Overall capacity is projected to reach 67,000-70,000 tons by the end of FY27.
Proactive Raw Material Management and Price Pass-through
Despite significant raw material price fluctuations, especially in March 2026, Mold-Tek successfully passed on the entire price increases to its clients across all segments. Management noted that clients have adapted to more frequent price corrections, now occurring monthly or fortnightly, compared to quarterly previously. The company's strong relationships with suppliers like Reliance, Indian Oil, and HML ensured timely material procurement, even during periods of difficulty, leading to client retention and increased call-ups from older clients like Berger and Nerolac.
Ambitious FY27 Targets and Outlook
For FY27, Mold-Tek has set ambitious targets, aiming for overall value growth of 13-15% and volume growth of 10-15%, with a revenue target exceeding INR1,000 crores. Pharma revenue is projected to reach INR50-55 crores, representing a 50% growth from FY26. The company targets an overall EBITDA of INR210 crores for FY27, a 20% increase from INR173 crores in FY26. Return on Capital Employed (ROCE) is expected to improve to 13.5-14% in FY27 and approximately 15% by FY28.
Challenges in Lubricant Segment and Working Capital
The Lubricant segment remains a concern, experiencing a 'disappointing trend' and overall market stagnation, with management not anticipating significant growth in the coming years. The company lost a substantial BPCL contract worth INR14-15 crores due to L1 tendering, impacting sales. Additionally, working capital days have stretched due to high material purchase prices, the necessity to maintain 3-month inventory for Pharma products, and the Pharma industry's 90-110 day payment cycles for debtors.